Losartan for the Treatment of Pediatric NAFLD
Public ClinicalTrials.gov record NCT03467217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
Study identification
- NCT ID
- NCT03467217
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 8 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2018
- Primary completion
- Jun 29, 2020
- Completion
- Jun 29, 2020
- Last update posted
- Oct 20, 2021
2018 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | San Diego | California | 92103 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611-2605 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| St. Louis University | St Louis | Missouri | 63104 | — |
| Columbia University | New York | New York | 10032 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated NAFLD - Nonalcoholic Fatty Liver Disease trials
Other public records listing NAFLD - Nonalcoholic Fatty Liver Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07518784: Accurate Point of Care Liver Disease Diagnostics (Phase 2) Recruiting
- NCT02581085: Tocotrienol Against the Progression of End Stage Liver Disease Active, not recruiting
- NCT06932289: Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03467217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2021 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03467217 live on ClinicalTrials.gov.